Next Generation Sequencing in Diffuse Large B Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study Dubois et al. Summary Next Generation Sequencing in Diffuse Large B Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study...............................................................1 Supplemental Methods................................................. 2 Patient and tumor sample selection..................................2 COO molecular classification........................................2 Variant analysis and bioinformatics pipeline........................2 AID mutation analysis...............................................2 Protein representations.............................................3 Supplemental Figures................................................. 4 Figure S1: Variant filters applied to Lymphopanel NGS data..........4 Figure S2: Validation of variants according to SIFT and CADD scores.5 Figure S3: PMBL samples harbor more mutations than other DLBCL subtypes............................................................6 Figure S4: Role of AID-induced SHM in DLBCL.........................7 Figure S5: Mutation frequency by subtype............................8 Figure S6: Clustering of gene mutations according to subtype........9 Figure S7: Protein representations of observed mutations...........15 Figure S8: Correlations between age and specific gene mutations....16 Figure S9: Prognosis according to IPI and subtype..................18 Figure S10: Prognostic impact of gene mutations among the Lymphopanel........................................................19 Supplemental Tables................................................. 20 Table S1: Clinical characteristics of patients in our cohort.......20 Table S2: Overview of the Lymphopanel used for NGS analysis........21
83
Embed
Clinical Cancer Research · Web viewFigure S2: Validation of variants according to SIFT and CADD scores. (A) The CADD scores of the RELYSE study variants are compared to the CADD
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Next Generation Sequencing in Diffuse Large B Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study Dubois et al.
Summary
Next Generation Sequencing in Diffuse Large B Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study............................1
Supplemental Methods..................................................................................................................................2Patient and tumor sample selection...........................................................................................................2COO molecular classification....................................................................................................................2Variant analysis and bioinformatics pipeline.............................................................................................2AID mutation analysis...............................................................................................................................2Protein representations...............................................................................................................................3
Supplemental Figures....................................................................................................................................4Figure S1: Variant filters applied to Lymphopanel NGS data...................................................................4Figure S2: Validation of variants according to SIFT and CADD scores...................................................5Figure S3: PMBL samples harbor more mutations than other DLBCL subtypes.....................................6Figure S4: Role of AID-induced SHM in DLBCL....................................................................................7Figure S5: Mutation frequency by subtype................................................................................................8Figure S6: Clustering of gene mutations according to subtype.................................................................9Figure S7: Protein representations of observed mutations......................................................................15Figure S8: Correlations between age and specific gene mutations.........................................................16Figure S9: Prognosis according to IPI and subtype.................................................................................18Figure S10: Prognostic impact of gene mutations among the Lymphopanel..........................................19
Supplemental Tables....................................................................................................................................20Table S1: Clinical characteristics of patients in our cohort.....................................................................20Table S2: Overview of the Lymphopanel used for NGS analysis...........................................................21Table S3: Overview of pathway selection...............................................................................................22Table S4: Validation of variant filtering by an independent study of seven non-tumoral samples from DLBCL patients.......................................................................................................................................23Table S5: Validated variants....................................................................................................................47Table S6: Lymphopanel NGS detection of genes with high AID target frequencies..............................48Table S7: Prognostic impact of mutations in Lymphopanel genes.........................................................63
Supplemental MethodsPatient and tumor sample selectionPatients were stratified according to age and age-adjusted International Prognosis Index (aaIPI) and assigned to the following trials: LNH03-1B (aaIPI = 0, < 60 years old), LNH03-2B (aaIPI = 1, age < 60 years old), LNH03-3B and 39B (aaIPI = 2-3, age < 60 years old), LNH03-6B (aaIPI=0-3, age=60-80 years old), LNH03-7B (age > 80 years old), and LNH 01-5B (aaIPI = 2-3, age 60-65 years old). Details regarding the design and data management of the LNH 03-2B, 03-3B, 03-6B and 03-7B trials have been published (Ketterer et al, Ann Oncol, 2013; Molina et al, J Clin Oncol, 2014; Récher et al, Lancet, 2011; Fitoussi et al, Haematologica, 2011; Delarue et al, Lancet Oncol, 2013; Peyrade et al, Lancet Oncol, 2011).
COO molecular classificationSamples were analyzed with HGU133+2.0 Affymetrix GeneChip arrays (Affymetrix). The chips were scanned with an Affymetrix GeneChip Scanner 3000 and subsequent images were analyzed using Gene Chip® Operating Software (GCOS) 1.4. Raw feature normalization and quality check were handled using Bioconductor software (affy, affyQCReport, GCRMA), excluding multi-gene probesets (x). PMBL signature was established using hierarchical clustering (complete distance, Ward agglomeration) of a previously published gene signature (Rosenwald et al, J Exp Med, 2003), excluding TCL1A and E2F2 that could not be reliably measured on U133+2.0 arrays. The “other” subgroup was defined as samples not significantly determined as ABC or GCB subtype.
Variant analysis and bioinformatics pipelineTorrent Suite™ version 4.0 (Life Technologies) software was used to perform primary analysis, including signal processing, base calling, sequence alignment to the reference genome (hg19) and generation of Binary Alignment/Map (BAM) files. BAM files were used by Torrent Suite™’s Variant Caller (TVC) to detect point mutations as well as short insertions and deletions using the PGM Somatic Low Stringency profile. VCF files generated by Variant Caller were annotated by ANNOVAR (Wang et al, Nucleic Acids Res, 2010). Genes were identified using the Refseq database (version hg19_refGene). Variants were filtered according to mutation type: only frameshift and non-frameshift deletions, insertions or substitutions, splicing, nonsynonymous, stopgain or stoploss Single Nucleotide Variations (SNVs), and UTR3 or UTR5 were kept. Stopgain, frameshift and/or splicing SNVs are referred to in the article as truncating mutations. A normal probability plot defined thresholds separating true positives (confirmed by Sanger sequencing, TVC score ≥ 22) from true negatives (discredited by Sanger sequencing, TVC score < 9.5) and highlighted a gray zone (9.5 < TVC score < 22) in which variants must be confirmed by Sanger sequencing. When possible, insertion-deletions in homopolymeric regions were verified as well, regardless of TVC score. Highly recurrent variants (n ≥ 30) validated at least twice by Sanger sequencing were confirmed without further validation for all samples. Variants described as “nonpathogenic” or “probably nonpathogenic” in the ClinVar database (version hg19_clinvar_20140211) were discarded, as were those with predictive SIFT (version hg19_ljb23_sift) or CADD (version hg19_ljb26_cadd) scores >0.05 or <1.5 respectively, or with a frequency ≥ 1% in the 1000genomes database (version hg19_ALL.sites.2012_04) (detailed in Figures S1 and S2) (Kumar et al, Nat Protocols, 2009). We achieved a median uniformity of 92% [80%-94%] and a median on-target read percentage of 95% [86%-97%]. Further verification by Sanger sequencing was performed using a BigDye® Terminator v3.1 Cycle Sequencing Kit (Life Technologies) and an ABI PRISM 3130 analyzer (Life Technologies).
AID mutation analysisFor AID mutation analysis, synonymous variants were also included, and the Functional filter was not applied. Preferential DGYW/WRCH AID target sites were targeted (Rogozin et al, J. Immunol, 2004).
Protein representationsProtein representations were created using R software version 3.1.2. Domains were imported from the Pfam database and motifs from the Uniprot database. Exons were located using the CCDS database. Uniprot/Ensembl IDs used were as follows: BCL2 (P10415), B2M (P61769), BRAF (P15056), CARD11 (Q9BXL7), CD58 (P19256), CD79A (P11912), CD79B (P40259), CDKN2A p16 (P42771), CDKN2A p14 (Q8N726), CDKN2B (P42772), CIITA (P33076), CREBBP (Q92793), EP300 (Q09472), EZH2 (Q15910), FOXO1 (Q12778), GNA13 (Q14344), ID3 (Q02535), IRF4 (Q15306), ITPKB (P27987), MEF2B (Q02080), MFHAS1 (Q9Y4C4), KMT2D (O14686), MYC (P01106), MYD88 isoforms 67 (ENSP00000401399) and 69 (ENSP00000390565), NOTCH1 (P46531), NOTCH2 (Q04721), PIM1 (ENSP00000362608), PRDM1 (O75626), SOCS1 (O15524), STAT6 (P42226), TCF3 (ENSP00000344375), TNFAIP3 (P21580), TNFRSF14 (Q92956), TP53 (P04637), XPO1 (O14980). All protein representations are available in Figure S3.
Supplemental Figures
Figure S1: Variant filters applied to Lymphopanel NGS data.The numbers in the Venn diagram correspond to the number of variants left after filtering. The Quality Filter eliminated variants based on TVC score and Sanger sequencing confirmation when performed. The SNP Filter eliminated variants based on their type, their frequency in the 1000genomes database and their description in the ClinVar database. The Functional Filter eliminated variants based on their CADD or SIFT scores. A total of 1064 validated variants remained after applying all three filters.
Figure S2: Validation of variants according to SIFT and CADD scores.(A) The CADD scores of the RELYSE study variants are compared to the CADD scores of different ClinVar annotations. Using a CADD score threshold of 1.5 enables the filtering of most non-pathogenic variants, while maintaining all pathogenic and probably pathogenic variants. B: The CADD scores of variants present in the dbSNP and COSMIC databases are plotted, as is the 1.5 CADD score threshold. Using the threshold at 1.5 filters the majority of dbSNP variants, while maintaining the majority of COSMIC variants. (C) CADD versus SIFT scores of variants are plotted. We eliminated double negative variants (blue) and conserved variants with CADD and/or SIFT scores above the defined thresholds (orange and red).
A
B
C
Figure S3: PMBL samples harbor more mutations than other DLBCL subtypes.The number of variants was calculated for each sample and a boxplot of number of variants per sample according to subtype was generated. PMBL samples are significantly more frequently mutated than ABC, GCB or “other” subtypes combined (DLBCL).
Figure S4: Role of AID-induced SHM in DLBCL.(A) The percentage of transition and transversion variants per gene are plotted as a stacked bar chart, with a pie chart representing the percentage of transition, transversion and other variants among the total Lymphopanel. (B) AID mutation frequency (percentage of total variants located at preferential DGYW/WRCH AID target sites) was calculated for each gene in the Lymphopanel. (C) AID target site mutation rate (percentage of sequenced DGYW/WRCH AID target sites in each gene that were effectively mutated) was calculated for each gene in the Lymphopanel. Genes in the gray box are genes which have a significantly higher (PIM1, SOCS1, BCL2, MYC, GNA13 and ITPKB) or lower (KMT2D, EP300, CREBBP and TP53) AID target site mutation rate than expected, compared to the average of the Lymphopanel. PIM1, SOCS1 and BCL2 (pink) seem to represent a separate group with higher AID target site mutation rates than MYC, GNA13 and ITPKB (orange).
A
B
C
Figure S5: Mutation frequency by subtype. Gene mutation frequency by subtype is represented for ABC patients (A), GCB patients (B), PMBL patients (C) and “other” patients (D).
A B
C D
Figure S6: Clustering of gene mutations according to subtype.Unsupervised clustering was performed for ABC subtype patients (A), GCB subtype patients (B), “other” patients (C) and PMBL patients (D). Presence of a mutation in a given gene for a given patient is plotted as a filled-in square. Genes (rows) and samples (columns) are arranged according to hierarchical clustering.
Figure S7: Protein representations of observed mutations.Protein representations were rendered using domains imported from the Pfam database (green) and motifs from the Uniprot database (orange). Exons were located using the CCDS database and were numbered automatically, not counting non-coding and spliced exons. Blue shadowing indicated regions sequenced by Lymphopanel NGS. Substitutions are depicted as diamonds, insertions as triangles and deletions as rectangles whose length varies according to the deletion size. A color code is also applied, with blue indicating non-synonymous substitutions or non-frameshift insertions, yellow indicating insertions and frameshift deletions, and pink indicating stop-gain and stop-loss mutations. Blue shading indicates sequenced regions. IRF4, GNA13, B2M, ITPKB, MFHAS1 and XPO1 representations are shown in Figure 4.
Figure S8: Correlations between age and specific gene mutations.Box-plots representing age at diagnosis according to the mutated or WT status of a given gene are shown.
Figure S9: Prognosis according to IPI and subtype.Survival analysis was performed on patients treated with either R-ACVBP (A, C, E, G) or R-CHOP (B, D, F, H). OS and PFS were measured according to IPI (A, B and C, D) or subtype (E, F and G, H). OS and PFS were significantly decreased in both treatment groups for patients with an IPI of 3-5 as compared to patients with an IPI of 0-2. ABC subtype presented significantly worse OS and PFS than GCB in the R-CHOP treated group, but not in the R-ACVBP treated group.
Figure S10: Prognostic impact of gene mutations among the Lymphopanel.Survival curves were generated for gene mutations with uncorrected p-values < 0.05 (indicated in Table 1).
Supplemental TablesClinical Parameter Patients at diagnosis
(n=215)Gender M/F, n 108/107Age (years), median (range) 60 (19–87)IPI, n (%)
Gene AID target frequency (%) Multiple mutation frequency (%)
MYC 60.7 66.7
PIM1 59 71.6
CDKN2B 50 0 (only 2 variants)
MFHAS1 44.6 63.0
IRF4 42.4 38.1
PRDM1 40 32.0
BCL2 34.1 70.3
GNA13 33.3 57.8
SOCS1 32.2 70.3
MYD88 26.1 41.3
CIITA 21.7 38.5
ITPKB 19.7 60.4
NOTCH2 19 12.5
Table S6: Lymphopanel NGS detection of genes with high AID target frequencies.Genes included in this table present AID target frequencies superior to the average for the Lymphopanel. Boldface indicates genes previously identified as SHM targets in DLBCL. The multiple mutation frequency refers to the percentage of variants present in association with at least one other variant of the same gene for a given patient.
Gene Subtype Cohort Type Mutant (n) WT (n) HR p FDR
B2M ABC R-ACVBP OS 3 19 NA 5.69E-01 7.72E-01B2M ABC R-ACVBP PFS 3 19 1.01 [0.12-8.69] 9.95E-01 9.95E-01B2M ABC R-CHOP OS 4 50 NA 5.86E-02 7.72E-01B2M ABC R-CHOP PFS 4 50 NA 6.29E-02 8.30E-01B2M all R-ACVBP OS 20 63 0.37 [0.04-3.19] 3.68E-01 9.74E-01B2M all R-ACVBP PFS 20 63 0.66 [0.18-2.40] 5.29E-01 8.66E-01B2M all R-CHOP OS 16 100 0.11 [0.01-0.82] 3.13E-02 5.43E-01B2M all R-CHOP PFS 16 100 0.12 [0.03-0.55] 6.24E-03 3.25E-01B2M GC R-ACVBP OS 8 29 NA 2.93E-01 7.72E-01B2M GC R-ACVBP PFS 8 29 NA 1.77E-01 8.30E-01B2M GC R-CHOP OS 6 34 NA 1.85E-01 7.72E-01B2M GC R-CHOP PFS 6 34 NA 1.34E-01 8.30E-01B2M Other R-ACVBP OS 4 10 NA NA NAB2M Other R-ACVBP PFS 4 10 2.16 [0.13-34.61] 5.77E-01 8.97E-01B2M Other R-CHOP OS 3 14 NA 5.50E-01 7.72E-01B2M Other R-CHOP PFS 3 14 NA 3.68E-01 8.30E-01B2M PMBL R-ACVBP OS 5 5 1.12 [0.07-17.95] 9.37E-01 9.59E-01B2M PMBL R-ACVBP PFS 5 5 1.12 [0.07-17.95] 9.37E-01 9.89E-01B2M PMBL R-CHOP OS 3 2 NA NA NAB2M PMBL R-CHOP PFS 3 2 NA NA NABCL2 ABC R-ACVBP OS 0 22 1.50 [0.16-14.45] NA NABCL2 ABC R-ACVBP PFS 0 22 0.93 [0.11-8.00] NA NABCL2 ABC R-CHOP OS 1 53 2.35 [0.67-8.22] NA NABCL2 ABC R-CHOP PFS 1 53 2.57 [0.81-8.15] NA NABCL2 all R-ACVBP OS 7 76 1.50 [0.16-14.40] 7.27E-01 9.99E-01BCL2 all R-ACVBP PFS 7 76 0.98 [0.11-8.41] 9.83E-01 9.98E-01BCL2 all R-CHOP OS 15 101 1.60 [0.54-4.78] 3.98E-01 9.85E-01BCL2 all R-CHOP PFS 15 101 2.01 [0.78-5.14] 1.46E-01 7.20E-01BCL2 GC R-ACVBP OS 7 30 1.50 [0.16-14.45] 7.25E-01 8.76E-01BCL2 GC R-ACVBP PFS 7 30 0.93 [0.11-8.00] 9.51E-01 9.89E-01BCL2 GC R-CHOP OS 13 27 2.35 [0.67-8.22] 1.68E-01 7.72E-01BCL2 GC R-CHOP PFS 13 27 2.57 [0.81-8.15] 9.64E-02 8.30E-01BCL2 Other R-ACVBP OS 0 14 1.50 [0.16-14.45] NA NABCL2 Other R-ACVBP PFS 0 14 0.93 [0.11-8.00] NA NABCL2 Other R-CHOP OS 1 16 2.35 [0.67-8.22] NA NABCL2 Other R-CHOP PFS 1 16 2.57 [0.81-8.15] NA NABCL2 PMBL R-ACVBP OS 0 10 1.50 [0.16-14.45] NA NABCL2 PMBL R-ACVBP PFS 0 10 0.93 [0.11-8.00] NA NABCL2 PMBL R-CHOP OS 0 5 2.35 [0.67-8.22] NA NABCL2 PMBL R-CHOP PFS 0 5 2.57 [0.81-8.15] NA NABRAF ABC R-ACVBP OS 0 22 NA NA NABRAF ABC R-ACVBP PFS 0 22 NA NA NABRAF ABC R-CHOP OS 0 54 NA NA NABRAF ABC R-CHOP PFS 0 54 NA NA NABRAF all R-ACVBP OS 0 83 NA NA NABRAF all R-ACVBP PFS 0 83 NA NA NABRAF all R-CHOP OS 1 115 NA NA NA
BRAF all R-CHOP PFS 1 115 NA NA NABRAF GC R-ACVBP OS 0 37 NA NA NABRAF GC R-ACVBP PFS 0 37 NA NA NABRAF GC R-CHOP OS 0 40 NA NA NABRAF GC R-CHOP PFS 0 40 NA NA NABRAF Other R-ACVBP OS 0 14 NA NA NABRAF Other R-ACVBP PFS 0 14 NA NA NABRAF Other R-CHOP OS 1 16 NA NA NABRAF Other R-CHOP PFS 1 16 NA NA NABRAF PMBL R-ACVBP OS 0 10 NA NA NABRAF PMBL R-ACVBP PFS 0 10 NA NA NABRAF PMBL R-CHOP OS 0 5 NA NA NABRAF PMBL R-CHOP PFS 0 5 NA NA NACARD11 ABC R-ACVBP OS 5 17 NA 4.36E-01 7.72E-01CARD11 ABC R-ACVBP PFS 5 17 0.60 [0.07-5.13] 6.35E-01 9.07E-01CARD11 ABC R-CHOP OS 6 48 0.65 [0.15-2.75] 5.54E-01 7.72E-01CARD11 ABC R-CHOP PFS 6 48 0.55 [0.13-2.32] 4.08E-01 8.30E-01CARD11 all R-ACVBP OS 7 76 0.00 [0.00-Inf] 9.99E-01 9.99E-01CARD11 all R-ACVBP PFS 7 76 0.49 [0.06-3.86] 4.94E-01 8.66E-01CARD11 all R-CHOP OS 12 104 0.66 [0.20-2.16] 4.95E-01 9.99E-01CARD11 all R-CHOP PFS 12 104 0.76 [0.27-2.12] 5.94E-01 9.35E-01CARD11 GC R-ACVBP OS 1 36 0.00 [0.00-Inf] NA NACARD11 GC R-ACVBP PFS 1 36 0.49 [0.06-3.86] NA NACARD11 GC R-CHOP OS 5 35 0.81 [0.10-6.42] 8.42E-01 9.45E-01CARD11 GC R-CHOP PFS 5 35 0.66 [0.09-5.16] 6.93E-01 9.07E-01CARD11 Other R-ACVBP OS 1 13 NA NA NACARD11 Other R-ACVBP PFS 1 13 0.60 [0.07-5.13] NA NACARD11 Other R-CHOP OS 1 16 0.65 [0.15-2.75] NA NACARD11 Other R-CHOP PFS 1 16 0.55 [0.13-2.32] NA NACARD11 PMBL R-ACVBP OS 0 10 NA NA NACARD11 PMBL R-ACVBP PFS 0 10 0.60 [0.07-5.13] NA NACARD11 PMBL R-CHOP OS 0 5 0.65 [0.15-2.75] NA NACARD11 PMBL R-CHOP PFS 0 5 0.55 [0.13-2.32] NA NACD58 ABC R-ACVBP OS 0 22 NA NA NACD58 ABC R-ACVBP PFS 0 22 NA NA NACD58 ABC R-CHOP OS 4 50 2.27 [0.68-7.61] 1.71E-01 7.72E-01CD58 ABC R-CHOP PFS 4 50 2.12 [0.63-7.09] 2.12E-01 8.30E-01CD58 all R-ACVBP OS 9 74 0.55 [0.05-5.72] 6.14E-01 9.99E-01CD58 all R-ACVBP PFS 9 74 0.49 [0.05-4.66] 5.33E-01 8.66E-01CD58 all R-CHOP OS 12 104 2.13 [0.87-5.23] 9.92E-02 9.31E-01CD58 all R-CHOP PFS 12 104 2.36 [1.07-5.20] 3.27E-02 5.67E-01CD58 GC R-ACVBP OS 4 33 NA 4.96E-01 7.72E-01CD58 GC R-ACVBP PFS 4 33 NA 3.82E-01 8.30E-01CD58 GC R-CHOP OS 4 36 3.26 [0.67-15.76] 1.19E-01 7.72E-01CD58 GC R-CHOP PFS 4 36 2.44 [0.52-11.30] 2.40E-01 8.30E-01CD58 Other R-ACVBP OS 0 14 0.89 [0.06-14.36] NA NACD58 Other R-ACVBP PFS 0 14 0.89 [0.06-14.36] NA NACD58 Other R-CHOP OS 2 15 2.27 [0.68-7.61] NA NA
CD58 Other R-CHOP PFS 2 15 2.12 [0.63-7.09] NA NACD58 PMBL R-ACVBP OS 5 5 0.89 [0.06-14.36] 9.37E-01 9.59E-01CD58 PMBL R-ACVBP PFS 5 5 0.89 [0.06-14.36] 9.37E-01 9.89E-01CD58 PMBL R-CHOP OS 2 3 2.27 [0.68-7.61] NA NACD58 PMBL R-CHOP PFS 2 3 2.12 [0.63-7.09] NA NACD79A ABC R-ACVBP OS 0 22 NA NA NACD79A ABC R-ACVBP PFS 0 22 NA NA NACD79A ABC R-CHOP OS 0 54 NA NA NACD79A ABC R-CHOP PFS 0 54 NA NA NACD79A all R-ACVBP OS 0 83 NA NA NACD79A all R-ACVBP PFS 0 83 NA NA NACD79A all R-CHOP OS 2 114 NA NA NACD79A all R-CHOP PFS 2 114 NA NA NACD79A GC R-ACVBP OS 0 37 NA NA NACD79A GC R-ACVBP PFS 0 37 NA NA NACD79A GC R-CHOP OS 2 38 NA NA NACD79A GC R-CHOP PFS 2 38 NA NA NACD79A Other R-ACVBP OS 0 14 NA NA NACD79A Other R-ACVBP PFS 0 14 NA NA NACD79A Other R-CHOP OS 0 17 NA NA NACD79A Other R-CHOP PFS 0 17 NA NA NACD79A PMBL R-ACVBP OS 0 10 NA NA NACD79A PMBL R-ACVBP PFS 0 10 NA NA NACD79A PMBL R-CHOP OS 0 5 NA NA NACD79A PMBL R-CHOP PFS 0 5 NA NA NACD79B ABC R-ACVBP OS 4 18 NA 4.99E-01 7.72E-01CD79B ABC R-ACVBP PFS 4 18 2.02 [0.37-11.08] 4.06E-01 8.30E-01CD79B ABC R-CHOP OS 16 38 0.35 [0.12-1.02] 4.44E-02 7.72E-01CD79B ABC R-CHOP PFS 16 38 0.33 [0.11-0.95] 3.07E-02 8.30E-01CD79B all R-ACVBP OS 4 79 NA NA NACD79B all R-ACVBP PFS 4 79 NA NA NACD79B all R-CHOP OS 19 97 0.31 [0.11-0.90] 3.13E-02 5.43E-01CD79B all R-CHOP PFS 19 97 0.29 [0.10-0.83] 2.15E-02 5.58E-01CD79B GC R-ACVBP OS 0 37 NA NA NACD79B GC R-ACVBP PFS 0 37 NA NA NACD79B GC R-CHOP OS 2 38 0.31 [0.11-0.90] NA NACD79B GC R-CHOP PFS 2 38 0.29 [0.10-0.83] NA NACD79B Other R-ACVBP OS 0 14 NA NA NACD79B Other R-ACVBP PFS 0 14 2.02 [0.37-11.08] NA NACD79B Other R-CHOP OS 1 16 0.35 [0.12-1.02] NA NACD79B Other R-CHOP PFS 1 16 0.33 [0.11-0.95] NA NACD79B PMBL R-ACVBP OS 0 10 NA NA NACD79B PMBL R-ACVBP PFS 0 10 2.02 [0.37-11.08] NA NACD79B PMBL R-CHOP OS 0 5 0.35 [0.12-1.02] NA NACD79B PMBL R-CHOP PFS 0 5 0.33 [0.11-0.95] NA NACDKN2A ABC R-ACVBP OS 0 22 NA NA NACDKN2A ABC R-ACVBP PFS 0 22 NA NA NACDKN2A ABC R-CHOP OS 2 52 NA NA NA
CDKN2A ABC R-CHOP PFS 2 52 NA NA NACDKN2A all R-ACVBP OS 0 83 NA NA NACDKN2A all R-ACVBP PFS 0 83 NA NA NACDKN2A all R-CHOP OS 3 113 NA NA NACDKN2A all R-CHOP PFS 3 113 NA NA NACDKN2A GC R-ACVBP OS 0 37 NA NA NACDKN2A GC R-ACVBP PFS 0 37 NA NA NACDKN2A GC R-CHOP OS 1 39 NA NA NACDKN2A GC R-CHOP PFS 1 39 NA NA NACDKN2A Other R-ACVBP OS 0 14 NA NA NACDKN2A Other R-ACVBP PFS 0 14 NA NA NACDKN2A Other R-CHOP OS 0 17 NA NA NACDKN2A Other R-CHOP PFS 0 17 NA NA NACDKN2A PMBL R-ACVBP OS 0 10 NA NA NACDKN2A PMBL R-ACVBP PFS 0 10 NA NA NACDKN2A PMBL R-CHOP OS 0 5 NA NA NACDKN2A PMBL R-CHOP PFS 0 5 NA NA NACDKN2B ABC R-ACVBP OS 0 22 NA NA NACDKN2B ABC R-ACVBP PFS 0 22 NA NA NACDKN2B ABC R-CHOP OS 0 54 NA NA NACDKN2B ABC R-CHOP PFS 0 54 NA NA NACDKN2B all R-ACVBP OS 0 83 NA NA NACDKN2B all R-ACVBP PFS 0 83 NA NA NACDKN2B all R-CHOP OS 1 115 NA NA NACDKN2B all R-CHOP PFS 1 115 NA NA NACDKN2B GC R-ACVBP OS 0 37 NA NA NACDKN2B GC R-ACVBP PFS 0 37 NA NA NACDKN2B GC R-CHOP OS 0 40 NA NA NACDKN2B GC R-CHOP PFS 0 40 NA NA NACDKN2B Other R-ACVBP OS 0 14 NA NA NACDKN2B Other R-ACVBP PFS 0 14 NA NA NACDKN2B Other R-CHOP OS 1 16 NA NA NACDKN2B Other R-CHOP PFS 1 16 NA NA NACDKN2B PMBL R-ACVBP OS 0 10 NA NA NACDKN2B PMBL R-ACVBP PFS 0 10 NA NA NACDKN2B PMBL R-CHOP OS 0 5 NA NA NACDKN2B PMBL R-CHOP PFS 0 5 NA NA NACIITA ABC R-ACVBP OS 3 19 NA 5.69E-01 7.72E-01CIITA ABC R-ACVBP PFS 3 19 NA 2.73E-01 8.30E-01CIITA ABC R-CHOP OS 7 47 1.37 [0.47-4.00] 5.59E-01 7.72E-01CIITA ABC R-CHOP PFS 7 47 1.29 [0.45-3.74] 6.38E-01 9.07E-01CIITA all R-ACVBP OS 11 72 0.72 [0.08-6.55] 7.67E-01 9.99E-01CIITA all R-ACVBP PFS 11 72 0.33 [0.04-2.64] 2.99E-01 7.56E-01CIITA all R-CHOP OS 16 100 1.38 [0.57-3.33] 4.71E-01 9.99E-01CIITA all R-CHOP PFS 16 100 1.02 [0.41-2.54] 9.72E-01 9.98E-01CIITA GC R-ACVBP OS 2 35 0.72 [0.08-6.55] NA NACIITA GC R-ACVBP PFS 2 35 0.33 [0.04-2.64] NA NACIITA GC R-CHOP OS 5 35 0.81 [0.10-6.39] 8.39E-01 9.45E-01
CIITA GC R-CHOP PFS 5 35 0.64 [0.08-4.98] 6.68E-01 9.07E-01CIITA Other R-ACVBP OS 2 12 1.73 [0.11-27.89] NA NACIITA Other R-ACVBP PFS 2 12 1.73 [0.11-27.89] NA NACIITA Other R-CHOP OS 0 17 1.37 [0.47-4.00] NA NACIITA Other R-CHOP PFS 0 17 1.29 [0.45-3.74] NA NACIITA PMBL R-ACVBP OS 4 6 1.73 [0.11-27.89] 6.95E-01 8.64E-01CIITA PMBL R-ACVBP PFS 4 6 1.73 [0.11-27.89] 6.95E-01 9.07E-01CIITA PMBL R-CHOP OS 4 1 1.37 [0.47-4.00] NA NACIITA PMBL R-CHOP PFS 4 1 1.29 [0.45-3.74] NA NACREBBP ABC R-ACVBP OS 1 21 1.04 [0.11-10.03] NA NACREBBP ABC R-ACVBP PFS 1 21 1.58 [0.29-8.66] NA NACREBBP ABC R-CHOP OS 4 50 0.84 [0.20-3.55] 8.09E-01 9.45E-01CREBBP ABC R-CHOP PFS 4 50 1.02 [0.24-4.31] 9.79E-01 9.89E-01CREBBP all R-ACVBP OS 11 72 0.92 [0.10-8.37] 9.40E-01 9.99E-01CREBBP all R-ACVBP PFS 11 72 1.14 [0.24-5.43] 8.73E-01 9.98E-01CREBBP all R-CHOP OS 28 88 1.42 [0.66-3.07] 3.69E-01 9.74E-01CREBBP all R-CHOP PFS 28 88 1.51 [0.74-3.05] 2.55E-01 7.56E-01CREBBP GC R-ACVBP OS 8 29 1.04 [0.11-10.03] 9.74E-01 9.75E-01CREBBP GC R-ACVBP PFS 8 29 1.58 [0.29-8.66] 5.92E-01 8.97E-01CREBBP GC R-CHOP OS 16 24 1.96 [0.55-6.96] 2.87E-01 7.72E-01CREBBP GC R-CHOP PFS 16 24 1.99 [0.63-6.28] 2.31E-01 8.30E-01CREBBP Other R-ACVBP OS 2 12 1.04 [0.11-10.03] NA NACREBBP Other R-ACVBP PFS 2 12 1.58 [0.29-8.66] NA NACREBBP Other R-CHOP OS 6 11 NA 6.15E-02 7.72E-01CREBBP Other R-CHOP PFS 6 11 5.87 [0.61-56.46] 8.22E-02 8.30E-01CREBBP PMBL R-ACVBP OS 0 10 1.04 [0.11-10.03] NA NACREBBP PMBL R-ACVBP PFS 0 10 1.58 [0.29-8.66] NA NACREBBP PMBL R-CHOP OS 2 3 0.84 [0.20-3.55] NA NACREBBP PMBL R-CHOP PFS 2 3 1.02 [0.24-4.31] NA NAEP300 ABC R-ACVBP OS 1 21 NA NA NAEP300 ABC R-ACVBP PFS 1 21 NA NA NAEP300 ABC R-CHOP OS 10 44 1.69 [0.68-4.22] 2.57E-01 7.72E-01EP300 ABC R-CHOP PFS 10 44 1.57 [0.63-3.92] 3.31E-01 8.30E-01EP300 all R-ACVBP OS 12 71 0.00 [0.00-Inf] 9.99E-01 9.99E-01EP300 all R-ACVBP PFS 12 71 0.80 [0.17-3.85] 7.83E-01 9.98E-01EP300 all R-CHOP OS 19 97 0.89 [0.37-2.12] 7.92E-01 9.99E-01EP300 all R-CHOP PFS 19 97 1.09 [0.51-2.33] 8.24E-01 9.98E-01EP300 GC R-ACVBP OS 6 31 NA 3.60E-01 7.72E-01EP300 GC R-ACVBP PFS 6 31 NA 2.45E-01 8.30E-01EP300 GC R-CHOP OS 5 35 NA 1.62E-01 7.72E-01EP300 GC R-CHOP PFS 5 35 NA 1.21E-01 8.30E-01EP300 Other R-ACVBP OS 3 11 NA NA NAEP300 Other R-ACVBP PFS 3 11 NA 5.13E-01 8.84E-01EP300 Other R-CHOP OS 3 14 NA 5.50E-01 7.72E-01EP300 Other R-CHOP PFS 3 14 1.65 [0.17-15.89] 6.62E-01 9.07E-01EP300 PMBL R-ACVBP OS 2 8 NA NA NAEP300 PMBL R-ACVBP PFS 2 8 NA NA NAEP300 PMBL R-CHOP OS 1 4 1.69 [0.68-4.22] NA NA
EP300 PMBL R-CHOP PFS 1 4 1.57 [0.63-3.92] NA NAEZH2 ABC R-ACVBP OS 0 22 NA NA NAEZH2 ABC R-ACVBP PFS 0 22 0.76 [0.09-6.52] NA NAEZH2 ABC R-CHOP OS 0 54 0.48 [0.06-3.78] NA NAEZH2 ABC R-CHOP PFS 0 54 0.37 [0.05-2.83] NA NAEZH2 all R-ACVBP OS 10 73 0.00 [0.00-Inf] 9.99E-01 9.99E-01EZH2 all R-ACVBP PFS 10 73 0.61 [0.07-4.89] 6.38E-01 9.37E-01EZH2 all R-CHOP OS 9 107 0.39 [0.05-2.99] 3.62E-01 9.74E-01EZH2 all R-CHOP PFS 9 107 1.08 [0.31-3.81] 9.07E-01 9.98E-01EZH2 GC R-ACVBP OS 8 29 NA 3.12E-01 7.72E-01EZH2 GC R-ACVBP PFS 8 29 0.76 [0.09-6.52] 8.03E-01 9.43E-01EZH2 GC R-CHOP OS 7 33 0.48 [0.06-3.78] 4.75E-01 7.72E-01EZH2 GC R-CHOP PFS 7 33 0.37 [0.05-2.83] 3.15E-01 8.30E-01EZH2 Other R-ACVBP OS 1 13 NA NA NAEZH2 Other R-ACVBP PFS 1 13 0.76 [0.09-6.52] NA NAEZH2 Other R-CHOP OS 2 15 0.48 [0.06-3.78] NA NAEZH2 Other R-CHOP PFS 2 15 0.37 [0.05-2.83] NA NAEZH2 PMBL R-ACVBP OS 1 9 NA NA NAEZH2 PMBL R-ACVBP PFS 1 9 0.76 [0.09-6.52] NA NAEZH2 PMBL R-CHOP OS 0 5 0.48 [0.06-3.78] NA NAEZH2 PMBL R-CHOP PFS 0 5 0.37 [0.05-2.83] NA NAFOXO1 ABC R-ACVBP OS 1 21 NA NA NAFOXO1 ABC R-ACVBP PFS 1 21 NA NA NAFOXO1 ABC R-CHOP OS 2 52 3.87 [1.00-15.07] NA NAFOXO1 ABC R-CHOP PFS 2 52 2.92 [0.79-10.87] NA NAFOXO1 all R-ACVBP OS 6 77 0.00 [0.00-Inf] 9.99E-01 9.99E-01FOXO1 all R-ACVBP PFS 6 77 0.00 [0.00-Inf] 9.98E-01 9.98E-01FOXO1 all R-CHOP OS 8 108 1.34 [0.41-4.39] 6.31E-01 9.99E-01FOXO1 all R-CHOP PFS 8 108 1.11 [0.34-3.63] 8.58E-01 9.98E-01FOXO1 GC R-ACVBP OS 4 33 NA 4.96E-01 7.72E-01FOXO1 GC R-ACVBP PFS 4 33 NA 3.82E-01 8.30E-01FOXO1 GC R-CHOP OS 5 35 3.87 [1.00-15.07] 3.53E-02 7.72E-01FOXO1 GC R-CHOP PFS 5 35 2.92 [0.79-10.87] 9.31E-02 8.30E-01FOXO1 Other R-ACVBP OS 0 14 NA NA NAFOXO1 Other R-ACVBP PFS 0 14 NA NA NAFOXO1 Other R-CHOP OS 1 16 3.87 [1.00-15.07] NA NAFOXO1 Other R-CHOP PFS 1 16 2.92 [0.79-10.87] NA NAFOXO1 PMBL R-ACVBP OS 1 9 NA NA NAFOXO1 PMBL R-ACVBP PFS 1 9 NA NA NAFOXO1 PMBL R-CHOP OS 0 5 3.87 [1.00-15.07] NA NAFOXO1 PMBL R-CHOP PFS 0 5 2.92 [0.79-10.87] NA NAGNA13 ABC R-ACVBP OS 2 20 NA NA NAGNA13 ABC R-ACVBP PFS 2 20 NA NA NAGNA13 ABC R-CHOP OS 5 49 3.68 [1.21-11.15] 1.36E-02 5.94E-01GNA13 ABC R-CHOP PFS 5 49 5.89 [1.86-18.64] 6.47E-04 3.04E-02GNA13 all R-ACVBP OS 13 70 0.42 [0.04-4.35] 4.64E-01 9.99E-01GNA13 all R-ACVBP PFS 13 70 0.24 [0.03-2.10] 1.97E-01 7.31E-01GNA13 all R-CHOP OS 15 101 1.82 [0.70-4.69] 2.17E-01 9.74E-01
GNA13 all R-CHOP PFS 15 101 1.62 [0.65-4.04] 2.98E-01 7.56E-01GNA13 GC R-ACVBP OS 3 34 NA 5.49E-01 7.72E-01GNA13 GC R-ACVBP PFS 3 34 NA 4.46E-01 8.30E-01GNA13 GC R-CHOP OS 6 34 0.84 [0.10-6.96] 8.69E-01 9.45E-01GNA13 GC R-CHOP PFS 6 34 0.70 [0.09-5.64] 7.40E-01 9.33E-01GNA13 Other R-ACVBP OS 2 12 0.73 [0.05-11.71] NA NAGNA13 Other R-ACVBP PFS 2 12 0.73 [0.05-11.71] NA NAGNA13 Other R-CHOP OS 2 15 3.68 [1.21-11.15] NA NAGNA13 Other R-CHOP PFS 2 15 5.89 [1.86-18.64] NA NAGNA13 PMBL R-ACVBP OS 6 4 0.73 [0.05-11.71] 8.24E-01 9.45E-01GNA13 PMBL R-ACVBP PFS 6 4 0.73 [0.05-11.71] 8.24E-01 9.56E-01GNA13 PMBL R-CHOP OS 2 3 3.68 [1.21-11.15] NA NAGNA13 PMBL R-CHOP PFS 2 3 5.89 [1.86-18.64] NA NAID3 ABC R-ACVBP OS 2 20 0.00 [0.00-Inf] NA NAID3 ABC R-ACVBP PFS 2 20 2.03 [0.43-9.60] NA NAID3 ABC R-CHOP OS 2 52 0.66 [0.09-4.87] NA NAID3 ABC R-CHOP PFS 2 52 0.99 [0.24-4.09] NA NAID3 all R-ACVBP OS 5 78 0.00 [0.00-Inf] 9.99E-01 9.99E-01ID3 all R-ACVBP PFS 5 78 2.03 [0.43-9.60] 3.72E-01 8.40E-01ID3 all R-CHOP OS 5 111 0.66 [0.09-4.87] 6.87E-01 9.99E-01ID3 all R-CHOP PFS 5 111 0.99 [0.24-4.09] 9.83E-01 9.98E-01ID3 GC R-ACVBP OS 1 36 0.00 [0.00-Inf] NA NAID3 GC R-ACVBP PFS 1 36 2.03 [0.43-9.60] NA NAID3 GC R-CHOP OS 1 39 0.66 [0.09-4.87] NA NAID3 GC R-CHOP PFS 1 39 0.99 [0.24-4.09] NA NAID3 Other R-ACVBP OS 2 12 0.00 [0.00-Inf] NA NAID3 Other R-ACVBP PFS 2 12 2.03 [0.43-9.60] NA NAID3 Other R-CHOP OS 1 16 0.66 [0.09-4.87] NA NAID3 Other R-CHOP PFS 1 16 0.99 [0.24-4.09] NA NAID3 PMBL R-ACVBP OS 0 10 0.00 [0.00-Inf] NA NAID3 PMBL R-ACVBP PFS 0 10 2.03 [0.43-9.60] NA NAID3 PMBL R-CHOP OS 1 4 0.66 [0.09-4.87] NA NAID3 PMBL R-CHOP PFS 1 4 0.99 [0.24-4.09] NA NAIRF4 ABC R-ACVBP OS 4 18 4.37 [0.27-69.94] 2.54E-01 7.72E-01IRF4 ABC R-ACVBP PFS 4 18 0.85 [0.10-7.34] 8.86E-01 9.89E-01IRF4 ABC R-CHOP OS 7 47 2.12 [0.80-5.67] 1.24E-01 7.72E-01IRF4 ABC R-CHOP PFS 7 47 1.98 [0.74-5.27] 1.64E-01 8.30E-01IRF4 all R-ACVBP OS 7 76 1.26 [0.15-10.58] 8.31E-01 9.99E-01IRF4 all R-ACVBP PFS 7 76 0.59 [0.08-4.60] 6.14E-01 9.37E-01IRF4 all R-CHOP OS 10 106 2.53 [1.10-5.87] 2.98E-02 5.43E-01IRF4 all R-CHOP PFS 10 106 2.01 [0.87-4.63] 1.02E-01 7.20E-01IRF4 GC R-ACVBP OS 2 35 1.26 [0.15-10.58] NA NAIRF4 GC R-ACVBP PFS 2 35 0.59 [0.08-4.60] NA NAIRF4 GC R-CHOP OS 2 38 2.53 [1.10-5.87] NA NAIRF4 GC R-CHOP PFS 2 38 2.01 [0.87-4.63] NA NAIRF4 Other R-ACVBP OS 0 14 4.37 [0.27-69.94] NA NAIRF4 Other R-ACVBP PFS 0 14 0.85 [0.10-7.34] NA NAIRF4 Other R-CHOP OS 0 17 2.12 [0.80-5.67] NA NA
IRF4 Other R-CHOP PFS 0 17 1.98 [0.74-5.27] NA NAIRF4 PMBL R-ACVBP OS 1 9 4.37 [0.27-69.94] NA NAIRF4 PMBL R-ACVBP PFS 1 9 0.85 [0.10-7.34] NA NAIRF4 PMBL R-CHOP OS 1 4 2.12 [0.80-5.67] NA NAIRF4 PMBL R-CHOP PFS 1 4 1.98 [0.74-5.27] NA NAITPKB ABC R-ACVBP OS 5 17 NA 4.36E-01 7.72E-01ITPKB ABC R-ACVBP PFS 5 17 NA 1.68E-01 8.30E-01ITPKB ABC R-CHOP OS 2 52 1.92 [0.41-9.07] NA NAITPKB ABC R-CHOP PFS 2 52 1.73 [0.38-7.94] NA NAITPKB all R-ACVBP OS 16 67 2.22 [0.53-9.32] 2.76E-01 9.74E-01ITPKB all R-ACVBP PFS 16 67 1.48 [0.47-4.68] 5.08E-01 8.66E-01ITPKB all R-CHOP OS 13 103 1.11 [0.34-3.67] 8.60E-01 9.99E-01ITPKB all R-CHOP PFS 13 103 0.92 [0.30-2.84] 8.91E-01 9.98E-01ITPKB GC R-ACVBP OS 8 29 3.89 [0.54-28.04] 1.47E-01 7.72E-01ITPKB GC R-ACVBP PFS 8 29 4.28 [0.84-21.88] 5.78E-02 8.30E-01ITPKB GC R-CHOP OS 5 35 1.92 [0.41-9.07] 4.00E-01 7.72E-01ITPKB GC R-CHOP PFS 5 35 1.73 [0.38-7.94] 4.73E-01 8.56E-01ITPKB Other R-ACVBP OS 1 13 NA NA NAITPKB Other R-ACVBP PFS 1 13 NA NA NAITPKB Other R-CHOP OS 2 15 1.92 [0.41-9.07] NA NAITPKB Other R-CHOP PFS 2 15 1.73 [0.38-7.94] NA NAITPKB PMBL R-ACVBP OS 2 8 NA NA NAITPKB PMBL R-ACVBP PFS 2 8 NA NA NAITPKB PMBL R-CHOP OS 4 1 1.92 [0.41-9.07] NA NAITPKB PMBL R-CHOP PFS 4 1 1.73 [0.38-7.94] NA NAKMT2D ABC R-ACVBP OS 8 14 1.69 [0.11-26.97] 7.09E-01 8.68E-01KMT2D ABC R-ACVBP PFS 8 14 0.79 [0.14-4.32] 7.83E-01 9.33E-01KMT2D ABC R-CHOP OS 23 31 1.33 [0.62-2.84] 4.67E-01 7.72E-01KMT2D ABC R-CHOP PFS 23 31 1.27 [0.59-2.72] 5.36E-01 8.84E-01KMT2D all R-ACVBP OS 28 55 1.07 [0.25-4.47] 9.31E-01 9.99E-01KMT2D all R-ACVBP PFS 28 55 0.80 [0.28-2.32] 6.85E-01 9.37E-01KMT2D all R-CHOP OS 56 60 1.28 [0.68-2.41] 4.40E-01 9.99E-01KMT2D all R-CHOP PFS 56 60 1.22 [0.67-2.23] 5.12E-01 8.66E-01KMT2D GC R-ACVBP OS 13 24 1.65 [0.23-11.72] 6.16E-01 8.12E-01KMT2D GC R-ACVBP PFS 13 24 1.66 [0.33-8.24] 5.32E-01 8.84E-01KMT2D GC R-CHOP OS 24 16 1.12 [0.31-4.01] 8.65E-01 9.45E-01KMT2D GC R-CHOP PFS 24 16 1.06 [0.33-3.36] 9.22E-01 9.89E-01KMT2D Other R-ACVBP OS 4 10 NA NA NAKMT2D Other R-ACVBP PFS 4 10 NA 3.88E-01 8.30E-01KMT2D Other R-CHOP OS 9 8 1.22 [0.07-20.14] 8.91E-01 9.57E-01KMT2D Other R-CHOP PFS 9 8 0.89 [0.13-6.37] 9.10E-01 9.89E-01KMT2D PMBL R-ACVBP OS 3 7 NA 3.35E-01 7.72E-01KMT2D PMBL R-ACVBP PFS 3 7 NA 3.35E-01 8.30E-01KMT2D PMBL R-CHOP OS 0 5 1.33 [0.62-2.84] NA NAKMT2D PMBL R-CHOP PFS 0 5 1.27 [0.59-2.72] NA NAMEF2B ABC R-ACVBP OS 4 18 4.37 [0.27-69.94] 2.54E-01 7.72E-01MEF2B ABC R-ACVBP PFS 4 18 2.87 [0.52-15.84] 2.06E-01 8.30E-01MEF2B ABC R-CHOP OS 6 48 0.53 [0.13-2.24] 3.80E-01 7.72E-01
MEF2B ABC R-CHOP PFS 6 48 0.46 [0.11-1.95] 2.81E-01 8.30E-01MEF2B all R-ACVBP OS 12 71 0.90 [0.11-7.74] 9.27E-01 9.99E-01MEF2B all R-ACVBP PFS 12 71 1.57 [0.43-5.69] 4.91E-01 8.66E-01MEF2B all R-CHOP OS 19 97 0.74 [0.29-1.91] 5.37E-01 9.99E-01MEF2B all R-CHOP PFS 19 97 0.73 [0.31-1.74] 4.81E-01 8.66E-01MEF2B GC R-ACVBP OS 7 30 NA 3.45E-01 7.72E-01MEF2B GC R-ACVBP PFS 7 30 0.97 [0.11-8.30] 9.77E-01 9.89E-01MEF2B GC R-CHOP OS 11 29 1.69 [0.41-6.88] 4.61E-01 7.72E-01MEF2B GC R-CHOP PFS 11 29 1.24 [0.33-4.73] 7.52E-01 9.33E-01MEF2B Other R-ACVBP OS 1 13 4.37 [0.27-69.94] NA NAMEF2B Other R-ACVBP PFS 1 13 2.87 [0.52-15.84] NA NAMEF2B Other R-CHOP OS 1 16 0.53 [0.13-2.24] NA NAMEF2B Other R-CHOP PFS 1 16 0.46 [0.11-1.95] NA NAMEF2B PMBL R-ACVBP OS 0 10 4.37 [0.27-69.94] NA NAMEF2B PMBL R-ACVBP PFS 0 10 2.87 [0.52-15.84] NA NAMEF2B PMBL R-CHOP OS 1 4 0.53 [0.13-2.24] NA NAMEF2B PMBL R-CHOP PFS 1 4 0.46 [0.11-1.95] NA NAMFHAS1 ABC R-ACVBP OS 0 22 NA NA NAMFHAS1 ABC R-ACVBP PFS 0 22 NA NA NAMFHAS1 ABC R-CHOP OS 1 53 2.94 [0.62-13.87] NA NAMFHAS1 ABC R-CHOP PFS 1 53 2.78 [0.61-12.70] NA NAMFHAS1 all R-ACVBP OS 10 73 0.00 [0.00-Inf] 9.99E-01 9.99E-01MFHAS1 all R-ACVBP PFS 10 73 0.00 [0.00-Inf] 9.98E-01 9.98E-01MFHAS1 all R-CHOP OS 7 109 1.64 [0.55-4.85] 3.75E-01 9.74E-01MFHAS1 all R-CHOP PFS 7 109 2.15 [0.80-5.73] 1.28E-01 7.20E-01MFHAS1 GC R-ACVBP OS 5 32 NA 3.97E-01 7.72E-01MFHAS1 GC R-ACVBP PFS 5 32 NA 3.00E-01 8.30E-01MFHAS1 GC R-CHOP OS 3 37 2.94 [0.62-13.87] 1.53E-01 7.72E-01MFHAS1 GC R-CHOP PFS 3 37 2.78 [0.61-12.70] 1.70E-01 8.30E-01MFHAS1 Other R-ACVBP OS 2 12 NA NA NAMFHAS1 Other R-ACVBP PFS 2 12 NA NA NAMFHAS1 Other R-CHOP OS 1 16 2.94 [0.62-13.87] NA NAMFHAS1 Other R-CHOP PFS 1 16 2.78 [0.61-12.70] NA NAMFHAS1 PMBL R-ACVBP OS 3 7 NA 3.35E-01 7.72E-01MFHAS1 PMBL R-ACVBP PFS 3 7 NA 3.35E-01 8.30E-01MFHAS1 PMBL R-CHOP OS 2 3 2.94 [0.62-13.87] NA NAMFHAS1 PMBL R-CHOP PFS 2 3 2.78 [0.61-12.70] NA NAMYC ABC R-ACVBP OS 0 22 3.73 [0.39-35.89] NA NAMYC ABC R-ACVBP PFS 0 22 2.28 [0.26-19.71] NA NAMYC ABC R-CHOP OS 4 50 NA 1.01E-01 7.72E-01MYC ABC R-CHOP PFS 4 50 NA 9.11E-02 8.30E-01MYC all R-ACVBP OS 4 79 NA NA NAMYC all R-ACVBP PFS 4 79 NA NA NAMYC all R-CHOP OS 8 108 0.90 [0.28-2.94] 8.66E-01 9.99E-01MYC all R-CHOP PFS 8 108 0.77 [0.24-2.50] 6.69E-01 9.37E-01MYC GC R-ACVBP OS 4 33 3.73 [0.39-35.89] 2.22E-01 7.72E-01MYC GC R-ACVBP PFS 4 33 2.28 [0.26-19.71] 4.40E-01 8.30E-01MYC GC R-CHOP OS 2 38 0.90 [0.28-2.94] NA NA
MYC GC R-CHOP PFS 2 38 0.77 [0.24-2.50] NA NAMYC Other R-ACVBP OS 0 14 3.73 [0.39-35.89] NA NAMYC Other R-ACVBP PFS 0 14 2.28 [0.26-19.71] NA NAMYC Other R-CHOP OS 1 16 NA NA NAMYC Other R-CHOP PFS 1 16 NA NA NAMYC PMBL R-ACVBP OS 0 10 3.73 [0.39-35.89] NA NAMYC PMBL R-ACVBP PFS 0 10 2.28 [0.26-19.71] NA NAMYC PMBL R-CHOP OS 1 4 NA NA NAMYC PMBL R-CHOP PFS 1 4 NA NA NAMYD88 ABC R-ACVBP OS 6 16 2.92 [0.18-46.84] 4.27E-01 7.72E-01MYD88 ABC R-ACVBP PFS 6 16 0.50 [0.06-4.33] 5.22E-01 8.84E-01MYD88 ABC R-CHOP OS 17 37 0.65 [0.27-1.56] 3.33E-01 7.72E-01MYD88 ABC R-CHOP PFS 17 37 0.67 [0.28-1.59] 3.59E-01 8.30E-01MYD88 all R-ACVBP OS 13 70 1.00 [0.11-8.84] 9.99E-01 9.99E-01MYD88 all R-ACVBP PFS 13 70 0.26 [0.03-2.01] 1.96E-01 7.31E-01MYD88 all R-CHOP OS 22 94 0.53 [0.23-1.25] 1.49E-01 9.31E-01MYD88 all R-CHOP PFS 22 94 0.63 [0.28-1.39] 2.50E-01 7.56E-01MYD88 GC R-ACVBP OS 4 33 NA 4.57E-01 7.72E-01MYD88 GC R-ACVBP PFS 4 33 NA 3.49E-01 8.30E-01MYD88 GC R-CHOP OS 4 36 NA 2.66E-01 7.72E-01MYD88 GC R-CHOP PFS 4 36 0.81 [0.10-6.30] 8.36E-01 9.58E-01MYD88 Other R-ACVBP OS 3 11 NA NA NAMYD88 Other R-ACVBP PFS 3 11 NA 3.88E-01 8.30E-01MYD88 Other R-CHOP OS 1 16 0.65 [0.27-1.56] NA NAMYD88 Other R-CHOP PFS 1 16 0.67 [0.28-1.59] NA NAMYD88 PMBL R-ACVBP OS 0 10 2.92 [0.18-46.84] NA NAMYD88 PMBL R-ACVBP PFS 0 10 0.50 [0.06-4.33] NA NAMYD88 PMBL R-CHOP OS 0 5 0.65 [0.27-1.56] NA NAMYD88 PMBL R-CHOP PFS 0 5 0.67 [0.28-1.59] NA NANOTCH1 ABC R-ACVBP OS 0 22 NA NA NANOTCH1 ABC R-ACVBP PFS 0 22 NA NA NANOTCH1 ABC R-CHOP OS 5 49 0.61 [0.08-4.57] 6.30E-01 8.18E-01NOTCH1 ABC R-CHOP PFS 5 49 0.47 [0.06-3.47] 4.47E-01 8.30E-01NOTCH1 all R-ACVBP OS 1 82 NA NA NANOTCH1 all R-ACVBP PFS 1 82 NA NA NANOTCH1 all R-CHOP OS 8 108 0.38 [0.05-2.81] 3.43E-01 9.74E-01NOTCH1 all R-CHOP PFS 8 108 0.20 [0.03-1.54] 1.23E-01 7.20E-01NOTCH1 GC R-ACVBP OS 0 37 NA NA NANOTCH1 GC R-ACVBP PFS 0 37 NA NA NANOTCH1 GC R-CHOP OS 1 39 0.38 [0.05-2.81] NA NANOTCH1 GC R-CHOP PFS 1 39 0.20 [0.03-1.54] NA NANOTCH1 Other R-ACVBP OS 1 13 NA NA NANOTCH1 Other R-ACVBP PFS 1 13 NA NA NANOTCH1 Other R-CHOP OS 1 16 0.61 [0.08-4.57] NA NANOTCH1 Other R-CHOP PFS 1 16 0.47 [0.06-3.47] NA NANOTCH1 PMBL R-ACVBP OS 0 10 NA NA NANOTCH1 PMBL R-ACVBP PFS 0 10 NA NA NANOTCH1 PMBL R-CHOP OS 1 4 0.61 [0.08-4.57] NA NA
NOTCH1 PMBL R-CHOP PFS 1 4 0.47 [0.06-3.47] NA NANOTCH2 ABC R-ACVBP OS 1 21 NA NA NANOTCH2 ABC R-ACVBP PFS 1 21 NA NA NANOTCH2 ABC R-CHOP OS 1 53 0.83 [0.10-6.65] NA NANOTCH2 ABC R-CHOP PFS 1 53 0.73 [0.09-5.71] NA NANOTCH2 all R-ACVBP OS 4 79 NA NA NANOTCH2 all R-ACVBP PFS 4 79 NA NA NANOTCH2 all R-CHOP OS 10 106 1.78 [0.58-5.46] 3.10E-01 9.74E-01NOTCH2 all R-CHOP PFS 10 106 1.26 [0.43-3.73] 6.74E-01 9.37E-01NOTCH2 GC R-ACVBP OS 2 35 NA NA NANOTCH2 GC R-ACVBP PFS 2 35 NA NA NANOTCH2 GC R-CHOP OS 5 35 0.83 [0.10-6.65] 8.64E-01 9.45E-01NOTCH2 GC R-CHOP PFS 5 35 0.73 [0.09-5.71] 7.67E-01 9.33E-01NOTCH2 Other R-ACVBP OS 1 13 NA NA NANOTCH2 Other R-ACVBP PFS 1 13 NA NA NANOTCH2 Other R-CHOP OS 4 13 4.51 [0.38-53.06] 1.97E-01 7.72E-01NOTCH2 Other R-CHOP PFS 4 13 1.85 [0.29-11.85] 5.10E-01 8.84E-01NOTCH2 PMBL R-ACVBP OS 0 10 NA NA NANOTCH2 PMBL R-ACVBP PFS 0 10 NA NA NANOTCH2 PMBL R-CHOP OS 0 5 0.83 [0.10-6.65] NA NANOTCH2 PMBL R-CHOP PFS 0 5 0.73 [0.09-5.71] NA NAPIM1 ABC R-ACVBP OS 6 16 2.92 [0.18-46.84] 4.27E-01 7.72E-01PIM1 ABC R-ACVBP PFS 6 16 3.03 [0.61-15.04] 1.53E-01 8.30E-01PIM1 ABC R-CHOP OS 19 35 0.52 [0.22-1.23] 1.27E-01 7.72E-01PIM1 ABC R-CHOP PFS 19 35 0.52 [0.22-1.23] 1.31E-01 8.30E-01PIM1 all R-ACVBP OS 9 74 1.20 [0.13-10.85] 8.73E-01 9.99E-01PIM1 all R-ACVBP PFS 9 74 1.59 [0.42-6.02] 4.93E-01 8.66E-01PIM1 all R-CHOP OS 25 91 0.54 [0.24-1.22] 1.40E-01 9.31E-01PIM1 all R-CHOP PFS 25 91 0.51 [0.23-1.14] 9.97E-02 7.20E-01PIM1 GC R-ACVBP OS 3 34 NA 5.26E-01 7.72E-01PIM1 GC R-ACVBP PFS 3 34 NA 4.26E-01 8.30E-01PIM1 GC R-CHOP OS 4 36 1.13 [0.14-9.10] 9.08E-01 9.59E-01PIM1 GC R-CHOP PFS 4 36 1.03 [0.13-8.07] 9.77E-01 9.89E-01PIM1 Other R-ACVBP OS 0 14 2.92 [0.18-46.84] NA NAPIM1 Other R-ACVBP PFS 0 14 3.03 [0.61-15.04] NA NAPIM1 Other R-CHOP OS 2 15 0.52 [0.22-1.23] NA NAPIM1 Other R-CHOP PFS 2 15 0.52 [0.22-1.23] NA NAPIM1 PMBL R-ACVBP OS 0 10 2.92 [0.18-46.84] NA NAPIM1 PMBL R-ACVBP PFS 0 10 3.03 [0.61-15.04] NA NAPIM1 PMBL R-CHOP OS 0 5 0.52 [0.22-1.23] NA NAPIM1 PMBL R-CHOP PFS 0 5 0.52 [0.22-1.23] NA NAPRDM1 ABC R-ACVBP OS 1 21 NA NA NAPRDM1 ABC R-ACVBP PFS 1 21 NA NA NAPRDM1 ABC R-CHOP OS 12 42 0.45 [0.15-1.36] 1.49E-01 7.72E-01PRDM1 ABC R-CHOP PFS 12 42 0.51 [0.18-1.48] 2.05E-01 8.30E-01PRDM1 all R-ACVBP OS 4 79 NA NA NAPRDM1 all R-ACVBP PFS 4 79 NA NA NAPRDM1 all R-CHOP OS 15 101 0.48 [0.18-1.29] 1.46E-01 9.31E-01
PRDM1 all R-CHOP PFS 15 101 0.51 [0.19-1.33] 1.66E-01 7.20E-01PRDM1 GC R-ACVBP OS 2 35 NA NA NAPRDM1 GC R-ACVBP PFS 2 35 NA NA NAPRDM1 GC R-CHOP OS 3 37 1.11 [0.14-8.82] 9.18E-01 9.59E-01PRDM1 GC R-CHOP PFS 3 37 0.89 [0.11-6.88] 9.08E-01 9.89E-01PRDM1 Other R-ACVBP OS 1 13 NA NA NAPRDM1 Other R-ACVBP PFS 1 13 NA NA NAPRDM1 Other R-CHOP OS 0 17 0.45 [0.15-1.36] NA NAPRDM1 Other R-CHOP PFS 0 17 0.51 [0.18-1.48] NA NAPRDM1 PMBL R-ACVBP OS 0 10 NA NA NAPRDM1 PMBL R-ACVBP PFS 0 10 NA NA NAPRDM1 PMBL R-CHOP OS 0 5 0.45 [0.15-1.36] NA NAPRDM1 PMBL R-CHOP PFS 0 5 0.51 [0.18-1.48] NA NASOCS1 ABC R-ACVBP OS 2 20 NA NA NASOCS1 ABC R-ACVBP PFS 2 20 NA NA NASOCS1 ABC R-CHOP OS 2 52 1.28 [0.27-6.04] NA NASOCS1 ABC R-CHOP PFS 2 52 0.96 [0.21-4.38] NA NASOCS1 all R-ACVBP OS 18 65 0.78 [0.12-5.07] 7.96E-01 9.99E-01SOCS1 all R-ACVBP PFS 18 65 0.43 [0.09-2.16] 3.05E-01 7.56E-01SOCS1 all R-CHOP OS 11 105 0.97 [0.33-2.81] 9.52E-01 9.99E-01SOCS1 all R-CHOP PFS 11 105 1.03 [0.40-2.68] 9.54E-01 9.98E-01SOCS1 GC R-ACVBP OS 6 31 NA 3.60E-01 7.72E-01SOCS1 GC R-ACVBP PFS 6 31 NA 2.45E-01 8.30E-01SOCS1 GC R-CHOP OS 6 34 1.28 [0.27-6.04] 7.54E-01 8.98E-01SOCS1 GC R-CHOP PFS 6 34 0.96 [0.21-4.38] 9.56E-01 9.89E-01SOCS1 Other R-ACVBP OS 3 11 NA NA NASOCS1 Other R-ACVBP PFS 3 11 NA 6.17E-01 9.06E-01SOCS1 Other R-CHOP OS 1 16 1.28 [0.27-6.04] NA NASOCS1 Other R-CHOP PFS 1 16 0.96 [0.21-4.38] NA NASOCS1 PMBL R-ACVBP OS 7 3 NA 3.35E-01 7.72E-01SOCS1 PMBL R-ACVBP PFS 7 3 NA 3.35E-01 8.30E-01SOCS1 PMBL R-CHOP OS 2 3 1.28 [0.27-6.04] NA NASOCS1 PMBL R-CHOP PFS 2 3 0.96 [0.21-4.38] NA NASTAT6 ABC R-ACVBP OS 0 22 NA NA NASTAT6 ABC R-ACVBP PFS 0 22 0.73 [0.08-6.25] NA NASTAT6 ABC R-CHOP OS 0 54 NA NA NASTAT6 ABC R-CHOP PFS 0 54 0.62 [0.08-4.84] NA NASTAT6 all R-ACVBP OS 16 67 0.18 [0.02-2.03] 1.65E-01 9.31E-01STAT6 all R-ACVBP PFS 16 67 0.41 [0.06-2.72] 3.58E-01 8.40E-01STAT6 all R-CHOP OS 8 108 0.22 [0.03-1.99] 1.79E-01 9.31E-01STAT6 all R-CHOP PFS 8 108 0.41 [0.09-1.78] 2.35E-01 7.56E-01STAT6 GC R-ACVBP OS 7 30 NA 3.12E-01 7.72E-01STAT6 GC R-ACVBP PFS 7 30 0.73 [0.08-6.25] 7.71E-01 9.33E-01STAT6 GC R-CHOP OS 4 36 NA 2.00E-01 7.72E-01STAT6 GC R-CHOP PFS 4 36 0.62 [0.08-4.84] 6.48E-01 9.07E-01STAT6 Other R-ACVBP OS 1 13 NA NA NASTAT6 Other R-ACVBP PFS 1 13 0.73 [0.08-6.25] NA NASTAT6 Other R-CHOP OS 1 16 NA NA NA
STAT6 Other R-CHOP PFS 1 16 0.62 [0.08-4.84] NA NASTAT6 PMBL R-ACVBP OS 8 2 NA NA NASTAT6 PMBL R-ACVBP PFS 8 2 0.73 [0.08-6.25] NA NASTAT6 PMBL R-CHOP OS 3 2 NA NA NASTAT6 PMBL R-CHOP PFS 3 2 0.62 [0.08-4.84] NA NATCF3 ABC R-ACVBP OS 1 21 NA NA NATCF3 ABC R-ACVBP PFS 1 21 NA NA NATCF3 ABC R-CHOP OS 0 54 NA NA NATCF3 ABC R-CHOP PFS 0 54 NA NA NATCF3 all R-ACVBP OS 2 81 NA NA NATCF3 all R-ACVBP PFS 2 81 NA NA NATCF3 all R-CHOP OS 1 115 NA NA NATCF3 all R-CHOP PFS 1 115 NA NA NATCF3 GC R-ACVBP OS 1 36 NA NA NATCF3 GC R-ACVBP PFS 1 36 NA NA NATCF3 GC R-CHOP OS 1 39 NA NA NATCF3 GC R-CHOP PFS 1 39 NA NA NATCF3 Other R-ACVBP OS 0 14 NA NA NATCF3 Other R-ACVBP PFS 0 14 NA NA NATCF3 Other R-CHOP OS 0 17 NA NA NATCF3 Other R-CHOP PFS 0 17 NA NA NATCF3 PMBL R-ACVBP OS 0 10 NA NA NATCF3 PMBL R-ACVBP PFS 0 10 NA NA NATCF3 PMBL R-CHOP OS 0 5 NA NA NATCF3 PMBL R-CHOP PFS 0 5 NA NA NATNFAIP3 ABC R-ACVBP OS 5 17 NA 4.36E-01 7.72E-01TNFAIP3 ABC R-ACVBP PFS 5 17 NA 1.42E-01 8.30E-01TNFAIP3 ABC R-CHOP OS 6 48 9.04 [2.82-28.98] 9.03E-06 7.86E-04TNFAIP3 ABC R-CHOP PFS 6 48 5.59 [1.91-16.39] 4.29E-04 3.04E-02TNFAIP3 all R-ACVBP OS 18 65 0.31 [0.03-3.01] 3.14E-01 9.74E-01TNFAIP3 all R-ACVBP PFS 18 65 0.42 [0.09-1.98] 2.71E-01 7.56E-01TNFAIP3 all R-CHOP OS 17 99 2.52 [0.96-6.63] 6.02E-02 7.83E-01TNFAIP3 all R-CHOP PFS 17 99 1.95 [0.81-4.73] 1.38E-01 7.20E-01TNFAIP3 GC R-ACVBP OS 4 33 NA 4.96E-01 7.72E-01TNFAIP3 GC R-ACVBP PFS 4 33 NA 3.82E-01 8.30E-01TNFAIP3 GC R-CHOP OS 5 35 0.97 [0.12-7.68] 9.75E-01 9.75E-01TNFAIP3 GC R-CHOP PFS 5 35 0.75 [0.10-5.84] 7.84E-01 9.33E-01TNFAIP3 Other R-ACVBP OS 3 11 NA NA NATNFAIP3 Other R-ACVBP PFS 3 11 2.83 [0.17-47.15] 4.50E-01 8.30E-01TNFAIP3 Other R-CHOP OS 2 15 9.04 [2.82-28.98] NA NATNFAIP3 Other R-CHOP PFS 2 15 5.59 [1.91-16.39] NA NATNFAIP3 PMBL R-ACVBP OS 6 4 0.58 [0.04-9.30] 6.95E-01 8.64E-01TNFAIP3 PMBL R-ACVBP PFS 6 4 0.58 [0.04-9.30] 6.95E-01 9.07E-01TNFAIP3 PMBL R-CHOP OS 4 1 9.04 [2.82-28.98] NA NATNFAIP3 PMBL R-CHOP PFS 4 1 5.59 [1.91-16.39] NA NATNFRSF14 ABC R-ACVBP OS 0 22 NA NA NATNFRSF14 ABC R-ACVBP PFS 0 22 0.54 [0.06-4.59] NA NATNFRSF14 ABC R-CHOP OS 2 52 NA NA NA
TNFRSF14 ABC R-CHOP PFS 2 52 NA NA NATNFRSF14 all R-ACVBP OS 13 70 0.00 [0.00-Inf] 9.99E-01 9.99E-01TNFRSF14 all R-ACVBP PFS 13 70 0.50 [0.06-4.13] 5.17E-01 8.66E-01TNFRSF14 all R-CHOP OS 11 105 0.31 [0.04-2.32] 2.51E-01 9.74E-01TNFRSF14 all R-CHOP PFS 11 105 0.23 [0.03-1.78] 1.61E-01 7.20E-01TNFRSF14 GC R-ACVBP OS 10 27 NA 2.30E-01 7.72E-01TNFRSF14 GC R-ACVBP PFS 10 27 0.54 [0.06-4.59] 5.63E-01 8.97E-01TNFRSF14 GC R-CHOP OS 4 36 NA 3.17E-01 7.72E-01TNFRSF14 GC R-CHOP PFS 4 36 NA 2.55E-01 8.30E-01TNFRSF14 Other R-ACVBP OS 3 11 NA NA NATNFRSF14 Other R-ACVBP PFS 3 11 NA 7.39E-01 9.33E-01TNFRSF14 Other R-CHOP OS 5 12 NA 1.60E-01 7.72E-01TNFRSF14 Other R-CHOP PFS 5 12 NA 9.97E-02 8.30E-01TNFRSF14 PMBL R-ACVBP OS 0 10 NA NA NATNFRSF14 PMBL R-ACVBP PFS 0 10 0.54 [0.06-4.59] NA NATNFRSF14 PMBL R-CHOP OS 0 5 NA NA NATNFRSF14 PMBL R-CHOP PFS 0 5 NA NA NATP53 ABC R-ACVBP OS 4 18 NA 4.99E-01 7.72E-01TP53 ABC R-ACVBP PFS 4 18 2.44 [0.44-13.60] 2.95E-01 8.30E-01TP53 ABC R-CHOP OS 10 44 1.23 [0.49-3.05] 6.61E-01 8.45E-01TP53 ABC R-CHOP PFS 10 44 1.29 [0.52-3.20] 5.86E-01 8.97E-01TP53 all R-ACVBP OS 8 75 1.68 [0.19-14.88] 6.43E-01 9.99E-01TP53 all R-ACVBP PFS 8 75 3.23 [0.98-10.67] 5.42E-02 7.04E-01TP53 all R-CHOP OS 23 93 1.06 [0.50-2.24] 8.89E-01 9.99E-01TP53 all R-CHOP PFS 23 93 1.07 [0.53-2.18] 8.48E-01 9.98E-01TP53 GC R-ACVBP OS 2 35 1.68 [0.19-14.88] NA NATP53 GC R-ACVBP PFS 2 35 3.23 [0.98-10.67] NA NATP53 GC R-CHOP OS 11 29 0.51 [0.11-2.44] 3.93E-01 7.72E-01TP53 GC R-CHOP PFS 11 29 0.71 [0.19-2.66] 6.08E-01 9.06E-01TP53 Other R-ACVBP OS 1 13 NA NA NATP53 Other R-ACVBP PFS 1 13 2.44 [0.44-13.60] NA NATP53 Other R-CHOP OS 1 16 1.23 [0.49-3.05] NA NATP53 Other R-CHOP PFS 1 16 1.29 [0.52-3.20] NA NATP53 PMBL R-ACVBP OS 1 9 NA NA NATP53 PMBL R-ACVBP PFS 1 9 2.44 [0.44-13.60] NA NATP53 PMBL R-CHOP OS 1 4 1.23 [0.49-3.05] NA NATP53 PMBL R-CHOP PFS 1 4 1.29 [0.52-3.20] NA NAXPO1 ABC R-ACVBP OS 0 22 1.60 [0.14-18.48] NA NAXPO1 ABC R-ACVBP PFS 0 22 1.16 [0.12-10.96] NA NAXPO1 ABC R-CHOP OS 0 54 NA NA NAXPO1 ABC R-CHOP PFS 0 54 NA NA NAXPO1 all R-ACVBP OS 5 78 1.60 [0.14-18.48] 7.07E-01 9.99E-01XPO1 all R-ACVBP PFS 5 78 1.16 [0.12-10.96] 8.99E-01 9.98E-01XPO1 all R-CHOP OS 4 112 NA NA NAXPO1 all R-CHOP PFS 4 112 NA NA NAXPO1 GC R-ACVBP OS 1 36 1.60 [0.14-18.48] NA NAXPO1 GC R-ACVBP PFS 1 36 1.16 [0.12-10.96] NA NAXPO1 GC R-CHOP OS 0 40 NA NA NA
XPO1 GC R-CHOP PFS 0 40 NA NA NAXPO1 Other R-ACVBP OS 1 13 2.16 [0.13-34.61] NA NAXPO1 Other R-ACVBP PFS 1 13 2.16 [0.13-34.61] NA NAXPO1 Other R-CHOP OS 0 17 NA NA NAXPO1 Other R-CHOP PFS 0 17 NA NA NAXPO1 PMBL R-ACVBP OS 3 7 2.16 [0.13-34.61] 5.77E-01 7.72E-01XPO1 PMBL R-ACVBP PFS 3 7 2.16 [0.13-34.61] 5.77E-01 8.97E-01XPO1 PMBL R-CHOP OS 4 1 NA NA NAXPO1 PMBL R-CHOP PFS 4 1 NA NA NA
Table S7: Prognostic impact of mutations in Lymphopanel genes.All genes were tested for prognostic impact, either over all subtypes or by subtype. Only patients with Rituximab (R)-based treatment were included in survival analysis, and were separated into two cohorts: patients treated with R-CHOP and patients treated with R-ACVBP. NA is given as a result for p-value or FDR when there are fewer than five patients in either the WT or the mutated group.